Press release
Astellas Pharma and BioFocus sign target discovery agreement
BioFocus announced today that it has signed a collaboration agreement with Astellas Pharma Inc. focused on discovering novel targets in the field of CNS disorders. Under the agreement, BioFocus will utilize its SilenceSelect® target discovery platform to deliver validated targets to enhance the Astellas neurology pipeline and will receive research funding and success payments based on the progress of the collaboration.“We are delighted to support Astellas Pharma in its research” said Dr Chris Newton, SVP Galapagos Services and Managing Director BioFocus. “Our target discovery offering allows clients to access a unique platform providing rapid identification of novel targets through a proven technology”.
About Astellas
Astellas Pharma Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceuticals. Astellas has approximately 16,000 employees worldwide. The organization is committed to becoming a global category leader in Urology, Immunology including Transplantation and Infectious Diseases, Oncology, Neuroscience, DM Complications and Metabolic Diseases. For more information on Astellas Pharma Inc., please visit the company website at www.astellas.com/en.
About BioFocus
BioFocus aims to expand its partners’ drug pipelines by accelerating the gene-to-drug candidate discovery process. This is achieved through a comprehensive discovery platform, which includes target discovery in human primary cells, focused as well as diverse compound libraries, in vitro and cell-based screening, structural biology, medicinal chemistry, ADME/PK services, supported by unique chemogenomic and informatics tools, and compound library acquisition, storage and distribution services. As a service division of Galapagos, BioFocus has over 245 employees in four countries worldwide. For more information visit www.biofocus.com.
BioFocus® and SilenceSelect® are trademarks of Galapagos NV and/or its affiliates © Copyright 2011 Galapagos NV.
Alto Marketing
Office 3 | Universal Marina | Crableck Lane | Sarisbury Green | Southampton | SO31 7AL
Product enquiries
BioFocus:
Kate Hilyard
Tel: +44 1799 533 500
Email: kate.hilyard@glpg.com
Media enquiries
Alto Marketing Limited:
David Robinson
Tel: +44 1489 557 672
Email: davidr@alto-marketing.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Astellas Pharma and BioFocus sign target discovery agreement here
News-ID: 175228 • Views: …
More Releases from BioFocus
Argenta and BioFocus announce two-year extension of drug discovery collaboration …
Galapagos NV (Euronext: GLPG) announced today that its service division Argenta has extended its integrated contract drug discovery agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). Total potential value of the contract extension is up to £21.5 million (€23.4 million).
This is the third such extension since the agreement was announced in December 2005. The agreement covers a number of drug discovery…
BioFocus and InterMed Discovery announce Marketing Collaboration
BioFocus, an integrated drug discovery service partner, and InterMed Discovery GmbH (IMD), a natural product lead-discovery company, today announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed.
Under the terms of the collaboration, IMD will make its natural product screening libraries available and provide follow-on services to BioFocus. BioFocus will then incorporate these as part of…
BioFocus enters collaboration with Michael J. Fox Foundation
BioFocus announced today that it has signed a collaboration agreement with The Michael J. Fox Foundation for Parkinson’s Research, a not-for-profit organization focused on developing therapies for Parkinson’s disease. Under the agreement, BioFocus will perform fragment-based screening, assay development and hit-finding programs, to identify compounds that have the basis for a novel Parkinson’s disease diagnostic test.
“We are delighted to have the opportunity to support The Michael J.…
BioFocus extends collaboration with Usher III Initiative
BioFocus announced today that it has expanded a collaboration with the Usher III Initiative, Inc., a non-profit organization focused on developing treatments for Usher syndrome type III, a rare genetic disorder that causes the loss of hearing and vision.
BioFocus and the Usher III Initiative began their collaboration in July 2010 with BioFocus performing an integrated drug discovery program encompassing medicinal chemistry, ADME and biological sciences, aiming at a…
More Releases for Astellas
Pouchitis Treatment Market | AbbVie, Alfasigma, Astellas Pharma, AstraZeneca
The global pouchitis treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the pouchitis treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants.
From the perspective of market dynamics, this report explores the factors driving the growth of the…
OAB Treatment Market 2020 Productivity Data Analysis by Key Company's (Astellas …
Global OAB Treatment Market: Overview
The overactive bladder treatment market includes various therapies, namely, anticholinergics, mirabegron, BOTOX, and neurostimulation used to treat the sudden, involuntary contraction of the muscle in the urinary bladder wall leading to urinary urgency, frequency, nocturia, and urge-incontinence
Get Access to Report Sample @ https://www.businessindustryreports.com/sample-request/240473
Global OAB Treatment Market: Growth Factors
The growth of market is majorly driven by the increasing geriatric population and consequently rising prevalence of bladder overactivity,…
What's driving the Diabetic Neuropathy Market Growth? Prominent Players: Pfizer, …
The Global Diabetic Neuropathy Market to gain from rapid technological advancements taking place in the market. Recently Fortune Business Insights has published a report, titled Diabetic Neuropathy Market Size, Share And Global Trend By Type (Peripheral, Proximal, Autonomic, Focal), By Drug Class (Non-steroidal Anti-inflammatory Drugs, Antisiezure Drugs, Opioid Drugs, Anti-depressants), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), And Geography Forecast Till 2026.
Browse Full Report@ https://www.fortunebusinessinsights.com/industry-reports/diabetic-neuropathy-market-100598
Top Key Players Covered:
Company…
Fidaxomicin Market Research Report - Global Forecast till 2023 | Astellas, Merck …
The research study presented here is a brilliant compilation of different types of analysis of critical aspects of the global Fidaxomicin market. It sheds light on how the global Fidaxomicin Market is expected to grow during the course of the forecast period. With SWOT analysis and Porter’s Five Forces analysis, it gives a deep explanation of the strengths and weaknesses of the global Fidaxomicin market and different players operating therein.…
Tacrolimus Market 2017- Astellas, Novartis, Hisun
Marketreports.biz, recently published a detailed market research study focused on the "Tacrolimus Market" across the global, regional and country level. The report provides 360° analysis of "Tacrolimus Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Tacrolimus industry, and estimates the future trend of Tacrolimus market on the basis of this…
Next Astellas Site will Implement Werum’s PAS-X
Next Astellas Site will Implement Werum’s PAS-X
One of the leading Japanese pharma groups chooses Werum again
Lueneburg, Germany, 24 April 2012 – Astellas Ireland Co. Ltd. (Kerry Plant) has decided to implement Werum´s PAS-X MES at its production facility in Killorglin, County Kerry, Ireland. The MES will introduce efficient and state-of-the-art paperless Electronic Batch Recording functionality supporting compliant, efficient and lean production processes. The MES will be fully integrated with the…
